Victor Lyamichev
Hoffmann-La Roche
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Victor Lyamichev.
Journal of Biological Chemistry | 2017
Wojtek Steffen; Fu Chong Ko; Jigar Patel; Victor Lyamichev; Thomas J. Albert; Jörg Benz; Markus G. Rudolph; Frank Bergmann; Thomas Streidl; Peter Kratzsch; Mara Boenitz-Dulat; Tobias Oelschlaegel; Michael Schraeml
Microbial transglutaminases (MTGs) catalyze the formation of Gln–Lys isopeptide bonds and are widely used for the cross-linking of proteins and peptides in food and biotechnological applications (e.g. to improve the texture of protein-rich foods or in generating antibody-drug conjugates). Currently used MTGs have low substrate specificity, impeding their biotechnological use as enzymes that do not cross-react with nontarget substrates (i.e. as bio-orthogonal labeling systems). Here, we report the discovery of an MTG from Kutzneria albida (KalbTG), which exhibited no cross-reactivity with known MTG substrates or commonly used target proteins, such as antibodies. KalbTG was produced in Escherichia coli as soluble and active enzyme in the presence of its natural inhibitor ammonium to prevent potentially toxic cross-linking activity. The crystal structure of KalbTG revealed a conserved core similar to other MTGs but very short surface loops, making it the smallest MTG characterized to date. Ultra-dense peptide array technology involving a pool of 1.4 million unique peptides identified specific recognition motifs for KalbTG in these peptides. We determined that the motifs YRYRQ and RYESK are the best Gln and Lys substrates of KalbTG, respectively. By first reacting a bifunctionalized peptide with the more specific KalbTG and in a second step with the less specific MTG from Streptomyces mobaraensis, a successful bio-orthogonal labeling system was demonstrated. Fusing the KalbTG recognition motif to an antibody allowed for site-specific and ratio-controlled labeling using low label excess. Its site specificity, favorable kinetics, ease of use, and cost-effective production render KalbTG an attractive tool for a broad range of applications, including production of therapeutic antibody-drug conjugates.
Scientific Reports | 2017
Victor Lyamichev; Lauren Goodrich; Eric Sullivan; Ryan Bannen; Joerg Benz; Thomas J. Albert; Jigar Patel
Considerable efforts have been made to develop technologies for selection of peptidic molecules that act as substrates or binders to a protein of interest. Here we demonstrate the combination of rational peptide array library design, parallel screening and stepwise evolution, to discover novel peptide hotspots. These hotspots can be systematically evolved to create high-affinity, high-specificity binding peptides to a protein target in a reproducible and digitally controlled process. The method can be applied to synthesize both linear and cyclic peptides, as well as peptides composed of natural and non-natural amino acid analogs, thereby enabling screens in a much diverse chemical space. We apply this method to stepwise evolve peptide binders to streptavidin, a protein studied for over two decades and report novel peptides that mimic key interactions of biotin to streptavidin.
Archive | 2009
Thomas J. Albert; Jigar Patel; Victor Lyamichev
Archive | 2015
Thomas J. Albert; Victor Lyamichev; Jigar Patel
Archive | 2015
Thomas J. Albert; Frank Bergmann; Victor Lyamichev; Jigar Patel; Michael Schaeml; Wojtek Steffen; Thomas Streidl
Archive | 2014
Thomas J. Albert; Jason E. Norton; Jigar Patel; Daniel Burgess; Victor Lyamichev; Michael Brockman
Archive | 2017
Thomas J. Albert; Frank Bergmann; Victor Lyamichev; Jigar Patel; Michael Schraeml; Wojtek Steffen
Archive | 2017
Victor Lyamichev; Jigar Patel; Eric Sullivan; Lauren Goodrich; Christian Klein
Archive | 2016
Thomas J. Albert; Ryan Bannen; Victor Lyamichev; Jigar Patel; Eric Sullivan
Archive | 2016
Jeremy Beauchamp; Per-Ola Freskgård; Eric Argirios Kitas; Victor Lyamichev; Jigar Patel